China’s top pricing regulator on Wednesday announced its decision to penalize US Medtronic for price fixing, the first penalty on a medical device maker handed down by the central authority.
Medtronic was fined for $17.27 million, 4 percent of the company’s annual sales in 2015, due to violating the anti-monopoly law and eliminating market competition of medical device manufacturing industry, according to the National Development and Reform Commission.
The investigation discovered that since at least 2014 the company had fixed the resale price through monopoly agreements with it trading counterparts, namely its distributors.
Competition among distributors plays a key role in ensuring the formation of a reasonable market price at the time when high-end implantable medical equipment market competition is not sufficient in China, according to the commission.
Full Content: China Daily
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC to Approve Exxon’s $64 Billion Deal with Pioneer Resources, Excludes
May 1, 2024 by
CPI
UK Competition Watchdog Raises Alarm Over Nvidia’s ARM Takeover
May 1, 2024 by
CPI
Sen. Klobuchar Urges Regulators to Probe Collusion in Health Care Pricing
May 1, 2024 by
CPI
Multiple States Join Tennessee’s Antitrust Lawsuit Against NCAA Over NIL Rules
May 1, 2024 by
CPI
NY AG Joins Suit Challenging NCAA’s Restrictions on Student Athlete NIL Rights
May 1, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI